Membrane-penetrating polypeptide and use thereof
By screening and designing novel membrane-penetrating peptides, the poor tissue targeting and toxicity risks of cell-penetrating peptides in existing technologies have been solved, achieving low-toxicity and high-efficiency drug delivery, which is suitable for the delivery of anti-tumor, antiviral and anti-multidrug-resistant drugs.
Patent Information
- Application Number
- PCT/CN2026/092617
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-04-23
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cell-penetrating peptides have poor tissue targeting and potential toxicity risks when used in vivo, and their cell-penetrating efficiency is limited by microenvironmental factors. Traditional delivery technologies also suffer from poor safety and complex operation.
To develop a novel membrane-penetrating polypeptide, its membrane-penetrating ability was verified at the eukaryotic cell level by screening a short peptide library. The amino acid sequence Val Val Val Leu Ser Phe Glu Leu Leu His and its derivatives were designed, and polymers were formed by combining conventional modifications and coupling. These polymers were then applied to recombinant vectors and host cells for the preparation of drugs or delivery vectors.
It achieves low-toxicity and high-efficiency transmembrane entry into cells, suitable for the delivery of antitumor, antiviral and anti-multidrug-resistant drugs, provides a theoretical basis for novel drug delivery carriers, and reduces operational complexity and safety risks.
Smart Images

Figure CN2026092617_12112026_PF_FP_ABST
Abstract
Description
A membrane-penetrating polypeptide and its application
[0001] This application claims priority to Chinese Patent Application No. CN202510579308.4, filed on May 7, 2025, entitled “A transmembrane polypeptide and its application,” the entire disclosure of which is incorporated herein by reference. Technical Field
[0002] This application relates to the field of biomedical technology, specifically to a transmembrane polypeptide and its applications. Background Technology
[0003] Peptides are bioactive molecules formed by amino acids linked by peptide bonds. Their molecular weight falls between that of small molecules and proteins, giving them a structural advantage in specifically binding to targets. Compared to large molecule drugs such as antibodies, peptides exhibit significantly lower immunogenicity; and compared to small molecule drugs, peptides, due to their larger molecular structure, are better suited to regulating protein-protein interactions, demonstrating higher targeting selectivity. The current drug development field faces the dual challenges of bottlenecks in small molecule compound development and excessively long antibody drug development cycles. This makes peptides, which combine molecular designability and biocompatibility, highly promising candidate drug carriers.
[0004] The hydrophobic barrier properties of the cell membrane lipid bilayer severely restrict the intracellular delivery efficiency of biomolecules such as peptides. Studies have found that naturally occurring protein transduction domains (PTDs), such as HIV TAT protein and Drosophila Antennapedia protein, can mediate the transmembrane transport of exogenous macromolecules through their core transmembrane sequences (e.g., TAT47-57, Penetrantin). These short peptides with membrane-penetrating capabilities are collectively referred to as cell-penetrating peptides (CPPs), characterized by non-destructive transmembrane transport and generally having a molecular weight less than 3 kDa. With the addition of artificially designed peptides such as MPG and oligoarginine, the CPP family has become an important research direction in the field of drug delivery.
[0005] The core value of CPPs lies in their flexible drug conjugation capabilities. They can carry therapeutic payloads such as nucleic acids, proteins, and even nanoparticles through covalent bonds or physical adsorption, overcoming the bottlenecks of traditional delivery technologies such as liposome encapsulation and electroporation, which suffer from low transfection efficiency and significant cell damage. However, existing CPP systems still face two major drawbacks: first, their reliance on cation-mediated non-specific membrane penetration mechanisms (such as the arginine-rich TAT peptide) leads to poor tissue targeting and potential toxicity risks during in vivo application; second, membrane penetration efficiency is constrained by microenvironmental factors, such as insufficient PEG deshielding efficiency within tumor tissue, which significantly affects delivery performance. Currently, commonly used preclinical techniques such as viral vectors and microinjection also suffer from poor safety and operational complexity. Therefore, developing novel peptide delivery systems that combine high penetration efficiency with precise targeting characteristics has significant research value and clinical application prospects. Summary of the Invention
[0006] The purpose of this application is to provide a novel transmembrane polypeptide and its application. The following is a detailed description of this application.
[0007] In a first aspect, this application provides a membrane-penetrating polypeptide comprising:
[0008] (1) The amino acid sequence shown in SEQ ID NO:1;
[0009] Or, (2) has an amino acid sequence that is at least 50% homologous to the amino acid sequence shown in (1);
[0010] Alternatively, (3) an amino acid sequence obtained by replacing and / or adding at least one amino acid residue at any position in the amino acid sequences shown in (1) and (2).
[0011] The above-mentioned transmembrane polypeptides include the amino acid sequences shown in SEQ ID NO:3 to SEQ ID NO:27.
[0012] Secondly, this application provides a derivative of a membrane-penetrating polypeptide, which is a modified product obtained by modifying the above-mentioned membrane-penetrating polypeptide, or a polymer formed by coupling the above-mentioned membrane-penetrating polypeptide.
[0013] Among the aforementioned derivatives, modifications include conventional modifications and the attachment of tags for peptide or protein detection or purification.
[0014] Thirdly, this application provides a nucleic acid of a membrane-penetrating polypeptide, which is the nucleic acid of the aforementioned membrane-penetrating polypeptide, comprising:
[0015] (1) The nucleotide sequence shown in SEQ ID NO:2;
[0016] Or, (2) a nucleotide sequence having at least 50% homology to the nucleotide sequence shown in (1);
[0017] Or, (3) a nucleotide sequence obtained by replacing and / or adding at least three bases at any position in the nucleotide sequences shown in (1) and (2);
[0018] Alternatively, (4) a nucleotide sequence that can hybridize with the nucleotide sequences shown in (1), (2), and (3), and a nucleotide sequence that has at least 50% homology with them.
[0019] Fourthly, this application provides a recombinant vector containing the nucleic acid of the aforementioned membrane-penetrating polypeptide.
[0020] Fifthly, this application provides a host cell comprising the aforementioned recombinant vector.
[0021] Sixthly, this application provides the use of the above-mentioned transmembrane polypeptide in the preparation of drugs or in the preparation of transport vectors.
[0022] In the above applications, the drugs include antitumor drugs, antiviral drugs, and drugs against multidrug resistance.
[0023] In the above applications, the transport vectors include drug transport vectors, nuclear localization sequence transport vectors, probe transport vectors, and nanoparticle carriers.
[0024] In the above applications, the N-terminus or C-terminus of the amino acid sequence of the membrane-penetrating peptide is fused with the cell membrane-penetrating peptide.
[0025] Compared with the prior art, the advantages of this application include:
[0026] The cell-penetrating peptide obtained in this application was developed through screening a short peptide library and experimentally verifying its membrane-penetrating ability at the eukaryotic cell level. This peptide can penetrate the cell membrane and enter the cell to exert its delivery function. Exploring the mechanism of action of this technology provides a strong theoretical basis for the development of novel drug delivery carriers.
[0027] The polypeptide sequence of this application is short, has relatively better solubility, relatively lower toxicity, and is not easily degraded.
[0028] This application can be used in the preparation of drugs or delivery vectors, including antitumor drugs, antiviral drugs, and anti-multidrug resistance drugs. The transmembrane peptides serve as carriers to deliver drugs into cells to exert their functions. Attached Figure Description
[0029] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.
[0030] Figure 1(A) shows the HPLC purification of the L5 peptide.
[0031] Figure 1(B) shows the MS mass spectrometry molecular weight identification of the L5 peptide.
[0032] Figure 2 shows a laser confocal microscopy image of the L5-FAM peptide penetrating the cell membrane and entering the cell.
[0033] Figure 3 is a comparison of the membrane penetration efficiency of L5-FAM peptide and its derivative peptides.
[0034] Figure 4 shows a comparison of the membrane penetration efficiency of L5-FAM peptide and its amino acid mutant peptide.
[0035] Figure 5 shows a comparison of the membrane-penetrating ability of L5 peptide and L5-derived peptides with different lengths of peptide sequences.
[0036] Figure 6 shows the cell survival rate of A549 tumor cells in Example 6 of this application.
[0037] Figure 7(A) shows the inhibition efficiency of HIV Bal pseudovirus infection in Example 7 of this application.
[0038] Figure 7(B) shows the HIV-1 response in Embodiment 7 of this application. IIIB Graph showing the inhibition efficiency of live virus infection. Detailed Implementation
[0039] The technical solution of this application will be clearly and completely described below with reference to the accompanying drawings and specific embodiments. The embodiments described below are only for illustrating this application and should not be regarded as limiting the scope of this application. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall be followed. Where the manufacturers of reagents or instruments are not specified, they are all conventional products that can be purchased commercially.
[0040] A membrane-penetrating polypeptide comprising:
[0041] (1) The amino acid sequence shown in SEQ ID NO:1: Val Val Val Leu Ser Phe Glu Leu Leu His.
[0042] Or, (2) has an amino acid sequence that is at least 50% homologous to the amino acid sequence shown in (1), which may be 50%, 55%, 61%, 66%, 72%, 77%, 83%, 88%, 94% homology, etc.
[0043] Alternatively, (3) an amino acid sequence obtained by replacing and / or adding at least one amino acid residue at any position in the amino acid sequences shown in (1) and (2), including replacement and / or addition and / or deletion at any position within the peptide or protein sequence and at both ends of the sequence. Among the mutated amino acid residues, it is preferable to mutate them to other amino acids with side chain properties similar to the original amino acid residues. Amino acids with similar side chain properties are classified as hydrophilic amino acids (e.g., Arg, Asp, Asn, Cys, Glu, Gln, Gly, His, Lys, Ser, Thr), hydrophobic amino acids (e.g., Ala, Ile, Leu, Met, Phe, Pro, Trp, Tyr, Val), aliphatic amino acids (e.g., Gly, Ala, Val, Leu, Ile, Pro), hydroxyl side chains (e.g., Ser, Thr, Tyr), sulfur-containing side chains (e.g., Cys, Met), carboxyl and amide side chains (e.g., Asp, Asn, Glu, Gln), basic side chains (e.g., Arg, Lys, His), acidic side chains (e.g., Glu, Asp), and aromatic side chains (e.g., His, Phe, Tyr, Trp).
[0044] All of the above peptides retain cell membrane penetration activity.
[0045] A derivative of a membrane-penetrating peptide, which is a modified product obtained by modifying the aforementioned membrane-penetrating peptide, or a polymer formed by coupling the aforementioned membrane-penetrating peptide. Modifications include conventional modifications and the attachment of tags for peptide or protein detection or purification. Conventional modifications include acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, biotinylation, fluorescent group modification, PEGylation, lipoylation, and immobilization modification. Tags include His6, GST, EGFP, MBP, Nus, HA, IgG, FLAG, c-Myc, and Profinity eXact.
[0046] Furthermore, for example, peptides can be chemically modified, such as by labeling with fluorescein isothiocyanate (FITC), biotin, polyethylene glycol (PEG), immobilization, etc. (including but not limited to these); peptides can undergo sequence and structural modifications, such as acetylation, amidation, cyclization, glycosylation, phosphorylation, alkylation, and the introduction of non-peptide structures (including but not limited to these); or tags for peptide or protein detection and purification can be attached to the peptide or its derivatives, such as histidine tags (His6), glutathione S-transferase (GST), enhanced green fluorescent protein (EGFP), maltose-binding protein (MBP), N-site utilization protein (Nus), hemagglutinin tag protein (HA), immunoglobulin (IgG), FLAG tag protein, c-Myc tag protein, Profinity eXact fusion tag protein, etc. (including but not limited to these). All of the above modification methods are conventional methods for modifying peptides or proteins, and they can be degraded in vivo by lipases and other mechanisms.
[0047] A nucleic acid of a membrane-penetrating polypeptide, comprising:
[0048] (1) The nucleotide sequence shown in SEQ ID NO:2: GTAGTAGTACTTTCTTTTGAACTTCTACAT;
[0049] Or, (2) a nucleotide sequence having at least 50% homology to the nucleotide sequence shown in (1);
[0050] Or, (3) a nucleotide sequence obtained by replacing and / or adding at least three bases at any position in the nucleotide sequences shown in (1) and (2);
[0051] Or, (4) under highly stringent conditions, a nucleotide sequence that can hybridize with the nucleotide sequences shown in (1), (2), and (3), and a nucleotide sequence that has at least 50% homology with them.
[0052] A recombinant vector comprising nucleic acids of the aforementioned transmembrane polypeptide. The vector may include bacterial plasmids, phage particles, phage particles, yeast plasmids, plant virus vectors, animal virus vectors, and various other viral vectors commonly used in the art. Vectors applicable to this application include, but are not limited to: prokaryotic cell vectors (such as bacterial cloning / expression vectors), yeast cell vectors (such as Pichia pastoris vectors, Hansenula polymorpha vectors, etc.), insect cell vectors (such as baculovirus vectors, etc.), mammalian cell vectors (such as adenovirus vectors, vaccinia virus vectors, retrovirus vectors, lentivirus vectors, etc.), plant virus vectors, and mammalian organ-specific expression vectors such as mammary gland expression vectors; that is, any vector that can stably replicate and passage in host cells may be used. Preferred expression vectors include selectable marker genes, such as bacterial ampicillin resistance genes, tetracycline resistance genes, kanamycin resistance genes, streptomycin resistance genes, and chloramphenicol resistance genes; yeast neomycin resistance genes and zeocin resistance genes; yeast defective selectable markers, such as His, Leu, and Trp; and eukaryotic neomycin resistance genes, zeocin resistance genes, dihydrofolate reductase genes, histidine tag genes, and fluorescent protein marker genes. Those skilled in the art can utilize known biochemical and molecular biological techniques to construct expression vectors containing specific elements such as polynucleotide sequences, transcription and translation sequences, promoters, and selectable marker genes as described in this application. These vectors can be used to transform or transfect suitable host cells or organisms to obtain the desired target protein or polypeptide.
[0053] A host cell comprising the aforementioned recombinant vector. The cell may be a prokaryotic or eukaryotic cell, such as bacterial cells, yeast cells, plant cells, insect cells, mammalian cells, etc. After the host cell is transformed or transfected with a polynucleotide sequence containing the transmembrane polypeptide encoded by the present application, it can be used to produce the desired protein or polypeptide. Those skilled in the art can appropriately select suitable vectors and host cells, and are familiar with methods for efficient transformation or transfection of the vector into cells. The methods used include, but are not limited to, calcium chloride method, cesium chloride method, electroporation method, etc. for bacterial cells; electroporation method and protoplast fusion method, etc. for yeast cells; and liposome method, calcium phosphate coprecipitation method, electrofusion method, microinjection method, etc. for eukaryotic cells such as mammalian cells and insect cells.
[0054] The above-mentioned transmembrane peptides are used in the preparation of drugs or transport carriers. Drugs include antitumor drugs, antiviral drugs, and drugs against multidrug resistance. Administration can be performed in a manner conventional to those skilled in the art, such as injection, oral, pulmonary, nasal, or oral administration, with nasal, oral, and pulmonary administration being preferred. The dosage may vary depending on the formulation, desired duration of action, and the condition of the target population for prevention / treatment. The actual amount required for prevention / treatment (effective dose) can be determined by a physician based on the specific circumstances (e.g., the subject's condition, age, weight, etc.). Transport carriers include drug transport carriers (including those delivering small molecules, proteins, peptides, nucleic acids, etc.), nuclear localization sequence transport carriers, probe transport carriers, imaging agent transport carriers, and nanoparticle carriers. The N-terminus or C-terminus of the amino acid sequence of the transmembrane peptide is fused to the cell transmembrane peptide.
[0055] This application can also be applied to kits for preparing transmembrane drugs, including the polypeptide or its derivatives, nucleotides, carriers, host cells, and drugs described in this application. The kit includes instructions for use, which specify the administration method, such as the order of administration, timing, dosage, and route of administration.
[0056] The features and performance of this application will be further described in detail below with reference to embodiments:
[0057] 1. Reagents:
[0058] FAM: Widely used in fluorescent labeling research, a commercial product purchased from TargetMol.
[0059] 2. Cell lines:
[0060] MDCK cell line: dog kidney cell line, purchased from ATCC.
[0061] 293T cell line: human embryonic kidney cell line, commonly used for virus packaging and transfection, purchased from ATCC.
[0062] HeLa cell line: human cervical cancer cell line, purchased from ATCC.
[0063] A549 cell line: human non-small cell lung cancer cell line, purchased from ATCC.
[0064] U87 MG cell line: human astrocytoma cell line, purchased from ATCC.
[0065] MT2 cell line: human T-lymphoblastic leukemia cell line, purchased from ATCC.
[0066] This application obtains a short peptide capable of penetrating the cell membrane by performing fluorescent peptide penetration detection on a cell membrane penetration detection model. Furthermore, the short peptide sequence of this application has advantages such as better solubility, lower toxicity, less susceptibility to degradation, and greater ease of sequence optimization and modification, while also being less costly.
[0067] Example 1
[0068] This embodiment uses a solid-phase synthesis method to synthesize membrane-penetrating peptides. The specific method is as follows:
[0069] 3 g of RINK resin (substitution degree 0.3 mmol / g) was placed in a 150 mL reactor and soaked in 50 mL of dichloromethane (DCM) for 2 hours. The resin was then washed four times with nitro-dimethylformamide (DMF) at a volume three times its volume, and dried after each wash. A 20% piperidine / DMF solution was added to the reactor, and the mixture was shaken in a decolorizing shaker for 20 minutes to remove the Fmoc protecting groups from the resin. After this, the resin was washed four times with DMF and dried. A small amount of resin was tested for deprotection using the ninhydrin method: two drops each of test A and test B were added, and the mixture was reacted at 100 °C for 1 minute. The color change was observed; if the resin showed color, deprotection was successful.
[0070] Weigh the first C-terminal amino acid and 1-hydroxy-phenylhydrazine triazole (HOBT) into a 50 mL centrifuge tube, dissolve in 20 mL DMF, then add 3 mL N,N-diisopropylcarbodiimide (DIC), shake and mix for 1 minute until the solution is clear. Transfer to a reactor and react in a shaker at 30 °C for 2 hours. After the reaction, add a mixture of acetic anhydride, DIEA, and DCM (volume ratio 1:1:2) to cap the solution for 30 minutes, then wash four times with DMF and dry. Repeat the above deprotection steps (treatment with 20% piperidine / DMF for 20 minutes), and verify the deprotection effect by the ninhydrin method after washing.
[0071] The subsequent amino acid coupling was performed as follows: The target amino acid and HOBT were weighed into a 50 mL centrifuge tube, dissolved in 25 mL DMF, and then mixed with 2.5 mL DIC. The mixture was transferred to a reactor and reacted at 30 °C on a shaker for 1 hour. A small amount of resin was taken and the reaction progress was monitored using the ninhydrin method. If the resin was colorless, the condensation was complete; if it showed color, the reaction time was extended until completion. After condensation, the deprotection and washing steps were repeated, and the protecting group was checked for complete removal. All amino acids were coupled sequentially using this procedure.
[0072] After coupling with the last amino acid, the protecting group was removed and the resin was washed four times with DMF, followed by drying with methanol. The peptide was cleaved at room temperature with 95% cleavage buffer (trifluoroacetic acid: 1,2-ethylenedithiol: isopropylsilane: water = 95:2:2:1, 10 mL cleavage buffer per gram of resin). The peptide was then precipitated four times by centrifugation with ice-cold diethyl ether (cleavage buffer: ether = 1:9). The final product was purified by high-performance liquid chromatography (HPLC) on a C18 stationary phase. The mobile phase consisted of water containing 0.1% trifluoroacetic acid (Pump A) and acetonitrile containing 0.1% trifluoroacetic acid (Pump B), at a flow rate of 10 mL / min and a retention time of 20–30 min. The purification was repeated twice, followed by lyophilization to obtain the L5 peptide, whose amino acid sequence is Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro (SEQ ID NO:3).
[0073] The synthesized L5 peptide was analyzed by HPLC-MS as follows: Quality control analysis of the synthesized peptide L5 was performed using a Shimadzu HPLC-MS system. 2.0 mg of lyophilized sample was accurately weighed and dissolved in 1 mL of ultrapure aqueous solution containing 0.1% trifluoroacetic acid (TFA). After vortexing for 3 min and sonication at 40 kHz for 15 min, the sample was filtered through a 0.45 μm nylon membrane. Chromatographic separation was performed on an Inertsil ODS-SP reversed-phase column (4.6 × 250 mm, 5 μm). Mobile phase A was 0.1% TFA aqueous solution, and mobile phase B was 0.1% TFA acetonitrile solution. The flow rate was set at 1.0 mL / min, the column temperature was maintained at 30 °C, the detection wavelength was 220 nm, and the injection volume was 30 μL. The gradient elution program initially maintained 35% B phase for 2 min, linearly increased to 95% B within 25 min and maintained for 5 min, and then switched to 100% B to wash the column at 30 min before stopping the operation. Mass spectrometry was performed using ESI positive ion mode, with a nebulizer pressure of 35 psi, a drying gas temperature of 350℃, a capillary voltage of 4000V, and a scan range of m / z 400-2000. The threshold for triggering MS / MS acquisition was set to 5000 counts. During data analysis, the main peak purity was required to meet the requirement of an area ratio ≥95% at 220 nm wavelength. The deviation between the measured molecular weight and the theoretical value (1364.62 Da) was controlled within ±0.5 Da. The structural accuracy was verified by isotope distribution matching (≥85%) and MS / MS fragment coverage.
[0074] The results showed that, under the set chromatographic conditions, the target peptide L5 exhibited a single main peak at 13 minutes (Figure 1A), and detection at 220 nm wavelength showed that its chromatographic purity reached 97.16% (area normalization method), meeting the preset quality standard of ≥95%. MS results showed (Figure 1B): [M+H]+ Peak: Located at m / z 1365.72, representing the quasi-molecular ion formed by the combination of a compound molecule and a proton. The relative intensity of this peak is set to 100%, serving as the base peak to reflect its dominant position in the ion current. [M+2H] 2+ The peak at m / z 683.51 indicates that the molecule combines two protons and carries two units of positive charge. Calculations suggest a molecular weight of approximately 1365.02, consistent with [M+H]. + The calculated results of the peaks corroborate each other.
[0075] Example 2
[0076] L5 peptide membrane penetration ability detection.
[0077] The specific method for detecting L5 cell membrane penetration ability is as follows: MDCK cells were plated in glass-bottomed cell culture dishes. After 24 hours, when the cell confluence reached 60%, the cells were washed twice with PBS. The synthesized FAM fluorescently labeled L5-FAM peptide was diluted to 10 μM and added to the MDCK cells. The cells were incubated at 37°C in a 5% CO2 incubator for 1 hour. After 1 hour, the plates were washed three times with PBS, and then fixed with 1 mL of 4% paraformaldehyde. After 30 minutes, the cells were photographed using a laser confocal microscope. The results are shown in Figure 2.
[0078] The results showed that L5-FAM peptide was widely distributed in MDCK cells and that L5 peptide could penetrate the cell membrane.
[0079] Example 3
[0080] Comparative analysis of the membrane penetration ability of L5 peptide and its derivative peptides.
[0081] To investigate the key sites of action for L5 peptide to penetrate the membrane, L5 peptide was truncated to different degrees to obtain derivative peptides of L5 peptide, as shown in Table 1.
[0082] Table 1
[0083] Simultaneously, FAM fluorescent labeling was performed to obtain fluorescently labeled L5-derived peptides. The membrane-penetrating ability of these derived peptides and L5 peptides was compared. The specific method is as follows: 293T cells were plated 24 hours in advance. After the confluence reached 80%, the plates were washed twice with PBS. The synthesized FAM fluorescently labeled L5-FAM peptide and its derivative peptides were diluted to 10 μM and added to 293T cells. The cells were incubated at 37°C and 5% CO2 for 1 hour. After 1 hour, the 293T cells were aspirated with PBS, centrifuged at 4°C and 2000 rpm for 5 minutes, and the cell pellet was collected. The 293T cells were resuspended in flow cytometry buffer (PBS containing 2% FBS), and the process was repeated twice. The mean fluorescence intensity (MFI) was detected by flow cytometry. The results are shown in Figure 3.
[0084] The results showed that L5R2 peptide had the strongest membrane penetration ability, with a higher relative average fluorescence intensity than L5, followed by L5. L5R4, L5S2, and L5S3 all had good membrane penetration ability, and L5L2 also had a certain membrane penetration effect. All of them had higher average fluorescence intensity than the free FAM control.
[0085] Example 4
[0086] Comparative analysis of the membrane penetration ability of L5 peptide and its amino acid mutant derivative peptides.
[0087] To investigate the key amino acids for L5 peptide transmembrane penetration, an alanine mutation scan was performed on L5 peptide to obtain amino acid mutation-derived peptides, as shown in Table 2. Since the 11th amino acid of L5 is alanine, it was mutated to glycine or serine.
[0088] Table 2
[0089] Simultaneously, FAM fluorescent labeling was performed to obtain fluorescently labeled L5-derived peptides. The membrane-penetrating ability of these derived peptides and L5 peptides was compared. The specific method is as follows: 293T cells were plated 24 hours in advance. After the confluence reached 80%, the plates were washed twice with PBS. The synthesized FAM fluorescently labeled L5-FAM peptide and its derivative peptides were diluted to 10 μM and added to 293T cells. The cells were incubated at 37°C and 5% CO2 for 1 hour. After 1 hour, the 293T cells were aspirated with PBS, centrifuged at 4°C and 2000 rpm for 5 minutes, and the cell pellet was collected. The 293T cells were resuspended in flow cytometry buffer (PBS containing 2% FBS), and the process was repeated twice. The mean fluorescence intensity (MFI) was detected by flow cytometry. The results are shown in Figure 4.
[0090] The results showed that the average fluorescence intensity of cells treated with all amino acid mutant peptides was higher than that of the free FAM control. This indicates that the L5 amino acid mutant derivative peptides A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, G11, S11, and A12 can all penetrate the cell membrane and enter the cell.
[0091] Example 5
[0092] Detection of the membrane-penetrating ability of L5 peptides carrying peptides of different lengths.
[0093] To test the ability of L5 as a transport vector to carry cargo (including drugs, nuclear localization sequences, probes, nanoparticles, etc.) into cells, peptides of different lengths were designed and linked to the N-terminus or C-terminus of the transmembrane peptide L5. The L5-derived peptide sequences with different lengths of peptide sequences are shown in Table 3.
[0094] Table 3
[0095] Simultaneously, FAM fluorescent labeling was performed to obtain L5-derived peptides linked with polypeptide sequences of different lengths. The membrane-penetrating ability of these peptides was compared with that of the L5 peptide. The specific method is as follows: HeLa cells were plated 24 hours in advance, and after the confluence reached 80%, the plates were washed twice with PBS. The synthesized FAM fluorescently labeled L5-FAM peptide and its L5-derived peptides linked with polypeptide sequences of different lengths were diluted to 10 μM and added to HeLa cells. The cells were incubated at 37°C in a 5% CO2 incubator for 2 hours. After 2 hours, the cells were digested with 0.25% trypsin, centrifuged at 4°C and 2000 rpm for 5 minutes, and the cell pellet was collected. The HeLa cells were resuspended in flow cytometry buffer (PBS containing 2% FBS) and the process was repeated twice. The signal intensity was detected by flow cytometry. The results are shown in Figure 5.
[0096] The results showed that all derived peptides (L5C10L, L5N10L, L5C30L, L5N30L) obtained by linking 10 or 30 amino acid lengths to the C-terminus or N-terminus of L5 had membrane-penetrating ability, and their average fluorescence intensity was higher than that of the free FAM control. Among them, the membrane-penetrating ability of the linking peptide at the C-terminus of L5 was stronger than that of the linking peptide at the N-terminus of L5.
[0097] Example 6
[0098] Detection of the ability of L5 peptide to carry tumor cell apoptosis peptides into cells.
[0099] To test the ability of the L5 peptide to carry functional peptides into cells and exert their functions, based on the results of Example 4, a peptide called L5-p53, which fuses the tumor cell apoptosis peptide p53 to the C-terminus of L5, was designed and synthesized. Simultaneously, a positive control peptide, Tat-p53, was synthesized. The p53 peptide is a polypeptide derived from the human tumor suppressor gene p53 and does not possess membrane-penetrating ability itself. After being carried into cells by a vector, this peptide specifically relieves the inhibition of p53 protein by MDM2, leading to p53 protein accumulation and subsequently specifically killing tumor cells containing wild-type p53. The Tat peptide is a polypeptide derived from human immunodeficiency virus (HIV) and has been reported to possess membrane-penetrating ability. The peptide sequences are shown in Table 4.
[0100] Table 4
[0101] The antitumor function of these peptides was detected in a tumor cell model using the following method: A549 cells were plated 24 hours in advance. After the confluence reached 80%, peptides such as L5-p53 were diluted to 50 μM and added to the A549 cells. The cells were then incubated at 37°C in a 5% CO2 incubator for 48 hours. After 48 hours, the supernatant was discarded, and a diluted working concentration of CCK8 solution was added. The cells were then incubated at 37°C in a 5% CO2 incubator for 2 hours. The absorbance (OD450) at 450 nm was read using a microplate reader. The results are shown in Figure 6.
[0102] The results showed that L5-p53 significantly reduced tumor cell survival rate, with a relative survival rate of 92% compared to the Vehicle treatment group, 52% in the positive control Tat-p53 treatment group, 100% in the p53 treatment group, 99% in the L5 treatment group, and 100% in the Vehicle treatment group. These results indicate that L5 can carry the p53 peptide into cells to exert its anti-tumor cell function.
[0103] Example 7
[0104] Detection of the ability of L5 peptide to carry anti-HIV viral peptides into cells to exert their functions.
[0105] To further investigate the ability of the L5 peptide to carry functional peptides into cells and exert their functions, a peptide, L5-CAI, was designed and synthesized, which fuses an anti-HIV viral peptide to the C-terminus of L5. Simultaneously, a positive control peptide, Tat-CAI, was synthesized. CAI (Capsid inhibitor) is a peptide-based HIV capsid inhibitor that exerts its antiviral function by antagonizing HIV capsid assembly and uncapsidation. It does not possess membrane-penetrating ability itself; however, by using a vector or modifying it to gain the ability to enter cells, it can exert its anti-HIV function. The peptide sequences are shown in Table 5.
[0106] Table 5
[0107] 1) Detection of L5-CAI anti-HIV activity using a pseudovirus model
[0108] The activity of L5-CAI against HIV pseudovirus was detected in a pseudovirus model as follows: U-87MG cells were plated 24 hours in advance. After the confluence reached 80%, L5-p53 and other peptides were serially diluted 3-fold, and the same volume of pseudovirus was added. The mixture was then added to A549 cells and incubated at 37°C with 5% CO2 for 16 hours. The supernatant was discarded, and complete culture medium was added for further incubation for 48 hours. After 48 hours, the supernatant was aspirated, and 1× cell lysis buffer was added to the cells. The cells were lysed at room temperature for 40 minutes. The cell lysate was then mixed by pipetting and transferred to 96-well plates. Luciferase substrate was prepared, and an equal volume was added to the plates. The plates were immediately placed in a microplate reader to detect relative luciferase unit (RLU) activity, protected from light. The strength of this activity reflects the viral infection level, and the results are shown in Figure 7(A).
[0109] The results showed that the half-maximal inhibitory concentration (IC50) of L5-CAI against HIV Bal pseudovirus was 6.55 μM, while the IC50 of the positive control peptide Tat-CAI was 48.51 μM. Both the CAI and L5 peptides had IC50 values greater than 50 μM. These results indicate that L5 can carry the CAI peptide into cells to exert its anti-HIV pseudovirus infection effect.
[0110] 2) Detection of the anti-HIV activity of L5-CAI by live virus
[0111] The anti-HIV activity of L5-CAI was detected in a live virus model as follows: MT2 cells were seeded in 96-well plates 1 hour in advance (20,000 cells / well). L5-p53 and other peptides were serially diluted 3-fold, and the same volume of HIV-1 was added. IIIB After incubating the live virus, mix thoroughly and incubate at 37°C for 1 hour. After incubation, add the polypeptide-virus mixture to the cells. Incubate at 37°C in a 5% CO2 incubator for 16 hours, then discard 3 / 4 of the supernatant and add the same volume of complete culture medium, continuing incubation for another 72 hours. After 72 hours, lyse the cells with 2.5% Triton X-100, and detect the p24 antigen content in the supernatant using a double-antibody sandwich ELISA. Calculate the inhibition rate based on the absorbance at 450 nm. The results are shown in Figure 7(B).
[0112] The results showed that L5-CAI was effective against HIV-1. IIIBThe half-maximal inhibitory concentration (IC50) of the live virus was 7.73 μM, while the IC50 of the control peptide Tat-CAI was 10.76 μM. The IC50 of both the CAI and L5 peptides was greater than 100 μM. These results indicate that L5 can carry the CAI peptide into cells to exert its anti-HIV live virus infection effect.
[0113] Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein, and such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of this application.
Claims
1. A membrane-penetrating polypeptide, wherein, It includes: (1) The amino acid sequence shown in SEQ ID NO:1; Or, (2) has an amino acid sequence that is at least 50% homologous to the amino acid sequence shown in (1); Alternatively, (3) an amino acid sequence obtained by replacing and / or adding at least one amino acid residue at any position in the amino acid sequences shown in (1) and (2).
2. Derivatives of transmembrane peptides, among which, It is a modified product obtained by modifying the membrane-penetrating polypeptide of claim 1, or a polymer formed by coupling the membrane-penetrating polypeptide of claim 1.
3. The membrane-penetrating polypeptide derivative according to claim 2, wherein, Modifications include routine modifications and the attachment of tags for peptide or protein detection or purification.
4. A nucleic acid of a transmembrane polypeptide, wherein, It is the nucleic acid of the transmembrane polypeptide of claim 1, comprising: (1) The nucleotide sequence shown in SEQ ID NO:2; Or, (2) a nucleotide sequence having at least 50% homology to the nucleotide sequence shown in (1); Or, (3) a nucleotide sequence obtained by replacing and / or adding at least three bases at any position in the nucleotide sequences shown in (1) and (2); Alternatively, (4) a nucleotide sequence that can hybridize with the nucleotide sequences shown in (1), (2), and (3), and a nucleotide sequence that has at least 50% homology with them.
5. A recombinant vector, wherein, It contains nucleic acids of the membrane-penetrating polypeptide as described in claim 4.
6. A host cell, wherein, It comprises the recombinant vector as described in claim 5.
7. The use of the membrane-penetrating polypeptide of claim 1 in the preparation of drugs or transport vectors.
8. The application according to claim 7, wherein, The drugs include antitumor drugs, antiviral drugs, and drugs against multidrug resistance.
9. The application according to claim 7, wherein, The transport vectors include drug transport vectors, nuclear localization sequence transport vectors, probe transport vectors, and nanoparticle carriers.
10. The application according to claim 7, wherein, The N-terminus or C-terminus of the amino acid sequence of the cell-penetrating polypeptide is fused to the cell-penetrating polypeptide.
